Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration

FtsJ RNA 2'-O-methyltransferase 1 (FTSJ1) is a member of the methyltransferase superfamily and is involved in the processing and modification of ribosomal RNA. We herein demonstrate that FTSJ1 favors TNBC progression. The knockdown of FTSJ1 inhibits TNBC cell proliferation and development, indu...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-01, Vol.16 (3), p.597
Main Authors: Sun, Yangqing, Liu, Qingqing, Zhong, Shangwei, Wei, Rui, Luo, Jun-Li
Format: Article
Language:English
Subjects:
Apoptosis
Breast cancer
Cancer
Cancer therapies
CD8 antigen
Cell culture
Cell proliferation
Chemotherapy
Cytotoxicity
Development and progression
Ethylenediaminetetraacetic acid
Genes
Immunotherapy
Infiltration
Lung cancer
Lymphocytes T
Medical prognosis
Metastases
Oncology, Experimental
Plasmids
Prognosis
Proteins
Ribosomal RNA
RNA modification
rRNA
Survival analysis
T cells
Transfer RNA
Transferases
Tumor microenvironment
Tumors
Wound healing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FtsJ RNA 2'-O-methyltransferase 1 (FTSJ1) is a member of the methyltransferase superfamily and is involved in the processing and modification of ribosomal RNA. We herein demonstrate that FTSJ1 favors TNBC progression. The knockdown of FTSJ1 inhibits TNBC cell proliferation and development, induces apoptosis of cancer cells, and increases the sensitivity of TNBC cells to T-cell-mediated cytotoxicity. Furthermore, the high expression of FTSJ1 in TNBC attenuates CD8+T cell infiltration in the tumor microenvironment (TME) correlated with poorer prognosis for clinical TNBC patients. In this study, we establish that FTSJ1 acts as a tumor promotor, is involved in cancer immune evasion, and may serve as a potential immunotherapy target in TNBC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16030597